Prediction of duration of hospitalization in respiratory syncytial virus infection

Pediatric Pulmonology

Volumn 33, Issue 6, 2002, Pages 453-457

  Kneyber, Martin C J ^a   Moons, Karel G M ^b   De Groot, Ronald ^a   Moll, Henriëtte A ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bronchiolitis; Epidemiology; Hospitalization; Lower respiratory tract infections; Prediction models; Respiratory syncytial virus

Indexed keywords

RIBAVIRIN;

ARTICLE; BRONCHIOLITIS; FEMALE; HOSPITALIZATION; HUMAN; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PREDICTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; UNIVERSITY HOSPITAL; VIRUS INFECTION;

FEMALE; HOSPITALS, PEDIATRIC; HOSPITALS, UNIVERSITY; HUMANS; INFANT; LENGTH OF STAY; LIKELIHOOD FUNCTIONS; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NETHERLANDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; ROC CURVE;

EID: 0036099586     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10099     Document Type: Article

References (14)

1. The respiratory syncytial virus (RSV) and its role in acute bronchiolitis
2. Prediction of the duration of hospitalization in patients with respiratory syncytial virus infection: Use of clinical parameters
3. Severity of illness models for respiratory syncytial virus-associated hospitalisation
4. International variation in the management of infants hospitalised with respiratory syncytial virus
5. Risk factors for respiratory syncytial virus associated apnoea
6. Regression with missing X's: A review
7. Duration of hospitalisation in previously well infants with respiratory syncytial virus infection
8. Risk factors for mechanical ventilation in respiratory syncytial virus infection
9. RSV what we now know
10. Relationship between clinical severity of RSV infection and subtype
11. Study of interobserver reliability in clinical assessment of RSV lower respiratory illness: A pediatric investigators collaborative network for infections in Canada (PICNIC) study
12. Reduction of respiratory syncytial virus hospitalisation among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
13. Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants